Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jul 21;76(3):292-302.
doi: 10.1016/j.jacc.2020.05.045.

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers

Peter Izmirly  1 , Mimi Kim  2 , Deborah M Friedman  3 , Nathalie Costedoat-Chalumeau  4 , Robert Clancy  5 , Joshua A Copel  6 , Colin K L Phoon  5 , Bettina F Cuneo  7 , Rebecca E Cohen  5 , Kimberly Robins  5 , Mala Masson  5 , Benjamin J Wainwright  5 , Noel Zahr  8 , Amit Saxena  5 , Jill P Buyon  9
Affiliations
Clinical Trial

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers

Peter Izmirly et al. J Am Coll Cardiol. .

Abstract

Background: Experimental and clinical evidence support the role of macrophage Toll-like receptor signaling in maternal anti-SSA/Ro-mediated congenital heart block (CHB).

Objectives: Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the historical 18% recurrence rate of CHB.

Methods: This multicenter, open-label, single-arm, 2-stage clinical trial was designed using Simon's optimal approach. Anti-SSA/Ro-positive mothers with a previous pregnancy complicated by CHB were recruited (n = 19 Stage 1; n = 35 Stage 2). Patients received 400 mg daily of HCQ prior to completion of gestational week 10, which was maintained through pregnancy. The primary outcome was 2° or 3° CHB any time during pregnancy, and secondary outcomes included isolated endocardial fibroelastosis, 1° CHB at birth and skin rash.

Results: By intention-to-treat (ITT) analysis, 4 of 54 evaluable pregnancies resulted in a primary outcome (7.4%; 90% confidence interval: 3.4% to 15.9%). Because 9 mothers took potentially confounding medications (fluorinated glucocorticoids and/or intravenous immunoglobulin) after enrollment but prior to a primary outcome, to evaluate HCQ alone, 9 additional mothers were recruited and followed the identical protocol. In the per-protocol analysis restricted to pregnancies exposed to HCQ alone, 4 of 54 (7.4%) fetuses developed a primary outcome as in the ITT. Secondary outcomes included mild endocardial fibroelastosis (n = 1) and cutaneous neonatal lupus (n = 4).

Conclusions: These prospective data support that HCQ significantly reduces the recurrence of CHB below the historical rate by >50%, suggesting that this drug should be prescribed for secondary prevention of fetal cardiac disease in anti-SSA/Ro-exposed pregnancies. (Preventive Approach to Congenital Heart Block With Hydroxychloroquine [PATCH]; NCT01379573).

Keywords: anti-SSA/Ro antibodies; congenital heart block; hydroxychloroquine; neonatal lupus; prevention.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram of PATCH study enrollment. In 13 enrolled mothers, despite being on 400mg HCQ by 10 weeks, consents were signed after 10 weeks, 11 before the first echocardiogram was performed. Two of these 13 agreed to be in the study prior to the first echo and taking 400mg HCQ, but consents were signed after the first echocardiogram. Dex=dexamethasone; HCQ=hydroxychloroquine; ITT=intention-to-treat; IVIG=intravenous immunoglobulin; PP=per-protocol
Central Illustration.
Central Illustration.
Prevention of recurrent anti-SSA/Ro-associated congenital heart block with hydroxychloroquine: two-stage design with results for intention-to-treat and per-protocol analyses.
See this image and copyright information in PMC

Comment in

References

    1. Jaeggi ET, Hornberger LK, Smallhorn JF, Fouron JC. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol 2005;26:16–21. - PubMed
    1. Brito-Zeron P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015;11:301–12. - PMC - PubMed
    1. Brucato A, Frassi M, Franceschini F et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001;44:1832–5. - PubMed
    1. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. The Journal of pediatrics 2003;142:678–83. - PubMed
    1. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004;50:3187–94. - PubMed

Publication types

Supplementary concepts

Associated data